Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progre...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2023-02-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2022-0362.pdf |
| _version_ | 1797871512017960960 |
|---|---|
| author | Sang Bong Ahn |
| author_facet | Sang Bong Ahn |
| author_sort | Sang Bong Ahn |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice. |
| first_indexed | 2024-04-10T00:45:01Z |
| format | Article |
| id | doaj.art-67b2e70c46eb4c65840ff58a56bdcce9 |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-04-10T00:45:01Z |
| publishDate | 2023-02-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-67b2e70c46eb4c65840ff58a56bdcce92023-03-14T01:46:51ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2023-02-0129SupplS150S15610.3350/cmh.2022.03621765Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developmentsSang Bong AhnNonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice.http://e-cmh.org/upload/pdf/cmh-2022-0362.pdfbiomarkerliver steatosisnonalcoholic fatty liver disease |
| spellingShingle | Sang Bong Ahn Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Clinical and Molecular Hepatology biomarker liver steatosis nonalcoholic fatty liver disease |
| title | Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments |
| title_full | Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments |
| title_fullStr | Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments |
| title_full_unstemmed | Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments |
| title_short | Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments |
| title_sort | noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease current and future developments |
| topic | biomarker liver steatosis nonalcoholic fatty liver disease |
| url | http://e-cmh.org/upload/pdf/cmh-2022-0362.pdf |
| work_keys_str_mv | AT sangbongahn noninvasiveserumbiomarkersforliversteatosisinnonalcoholicfattyliverdiseasecurrentandfuturedevelopments |